Table 2 |
|||||
|
Characteristics of applied therapy |
|||||
| Group 1 (N = 32) |
Group 2 (N = 29) |
||||
| Psychotropic drug |
Patients in monotherapy |
Patients in polytherapy |
|||
|
|
|||||
| N of patients |
dose range (mg/d) |
N of patients |
dose range(mg/d) |
||
|
|
|||||
| AD used |
|||||
|
|
|||||
| Antipsychotic |
|||||
| Ziprasidone |
3 |
120–160 |
1 |
120 |
map |
| Olanzapine |
4 |
10–20 |
7 |
5–15 |
Mir,ven,par,fluo |
| Clozapine |
1 |
100 |
- |
- |
- |
| Risperidone |
3 |
3–5 |
1 |
4 |
map |
| Sulpiride |
1 |
400 |
3 |
50–200 |
ser,clo |
| fluophenazine |
7 |
5–8 |
6 |
2–15 |
tia,ser,par,map |
| Haloperidol |
3 |
6–15 |
4 |
4–15 |
mir,map,esc,clo |
| Promazine |
- |
- |
4 |
75–350 |
tia,ven,map |
| Quetiapine |
- |
- |
2 |
300–500 |
par,fluo |
| zuclopenthixol |
- |
- |
1 |
10 |
Fluo |
|
|
|||||
| AP used |
|||||
|
|
|||||
| Antidepressant |
|||||
| Mirtazapine |
2 |
30 |
3 |
15–30 |
ol,hal |
| Fluvoxamine |
1 |
150 |
- |
- |
- |
| Tianeptin |
2 |
37.5 |
2 |
37.5 |
flu,pro, |
| Sertraline |
2 |
50–100 |
2 |
50 |
sul,flu |
| Venlafaxine |
2 |
37.5–75 |
4 |
37.5–150 |
ol,pro |
| Paroxetine |
- |
- |
4 |
10–40 |
Ol,flu,que |
| Maprotiline |
1 |
100 |
7 |
50–100 |
zip,ris,flu,hal |
| Fluoxetine |
- |
- |
3 |
20–40 |
ol,que,zuc |
| escitalopram |
- |
- |
1 |
15 |
Hal |
| clomipramine |
- |
- |
3 |
25 |
sul,hal |
|
AD – antidepressant: map-maprotiline, mir-mirtazapine, ven-venlafaxine, par-paroxetine, fluo-fluoxetine, ser-sertraline, clo-clomipramine, tia-tianeptin, esc-escitalopram AP -antipsychotic: ol-olanzapine, hal-haloperidol, flu-fluophenazine, pro-promazine, sul-sulpiride, que-quetiapine, zip-ziprasidone, ris-risperidone, zuc-zuclopenthixol | |||||
Sumić et al. Annals of General Psychiatry 2007 6:13 doi:10.1186/1744-859X-6-13 |
|||||
